Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:ANGEN's Return-on-Tangible-Equity is ranked worse than 76.52% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs IST:ANGEN: -29.93
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Return-on-Tangible-Equity Related Terms
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Return-on-Tangible-Equity Chart
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -56.03% mean?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) has a Return-on-Tangible-Equity of -56.03% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve and its competitors. According to the industry distribution chart, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve ranks #580 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 76.5%.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Return-on-Tangible-Equity too high?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current Return-on-Tangible-Equity is -56.03%. Based on the distribution chart, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve ranks #580 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve ranks #580 out of 758 companies for Return-on-Tangible-Equity. This places Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current Return-on-Tangible-Equity is -56.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock overvalued right now?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₺18.64, compared to a current price of ₺9.95 — trading 46.6% below its estimated fair value. The current Return-on-Tangible-Equity is -56.03%. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN), the current Return-on-Tangible-Equity is -56.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock appears to be undervalued.
The current stock price of ₺9.95 is trading 46.6% below its estimated GF Value™ of ₺18.64.
GuruFocus considers Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve to be Possible Value Trap.
Key valuation signals for IST:ANGEN:
Return-on-Tangible-Equity: -56.03%
GF Value™: ₺18.64 vs. price of ₺9.95 (46.6% below fair value)
No single metric tells the full story. See the IST:ANGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Business Description
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
58GF Score
Get the complete analysis for IST:ANGEN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ANGEN has been successfully added to your 
